IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy

Why It Matters

The device provides robust, fast verification for ultra‑high‑dose‑rate therapies, safeguarding patient safety while cementing IBA’s competitive edge in the expanding particle‑therapy market.

Key Takeaways

• First wireless 2D ion chamber array for particle therapy
• 1,521 chambers deliver seconds‑fast dose distribution readout
• Supports proton, carbon ion, FLASH, and ARC modalities
• Reduces setup time, integrates into existing workflows
• Enhances patient safety and plan verification confidence

Pulse Analysis

The global particle‑therapy sector is accelerating, with new proton and carbon‑ion centers opening across Europe, Asia, and North America. As treatment plans become increasingly complex—incorporating intensity‑modulated scanning, multi‑field optimization, and biologically‑guided dosing—the demand for precise, real‑time quality assurance has surged. Traditional QA tools often rely on wired detectors and time‑consuming calibrations, creating bottlenecks that can delay patient treatment schedules and increase operational costs.

myQA MatriXX AiR addresses these challenges by delivering a wireless, high‑resolution detector array that captures two‑dimensional dose distributions in seconds. Its 1,521 air‑vented ionization chambers provide granular spatial data, enabling clinicians to verify intricate dose gradients and verify compliance with emerging FLASH and ARC protocols that operate at ultra‑high dose rates. The wireless architecture eliminates cable clutter, shortens setup time, and integrates with existing treatment planning systems, allowing physicists to focus on analysis rather than hardware logistics.

For the industry, IBA’s launch signals a shift toward more agile, future‑ready QA solutions. Clinics adopting myQA MatriXX AiR can expect reduced QA turnaround, higher confidence in plan delivery, and a smoother transition to next‑generation radiotherapy techniques. This strengthens IBA’s market position as a one‑stop supplier of particle‑accelerator technology, dosimetry, and now advanced QA, potentially prompting competitors to accelerate their own wireless QA developments. As particle therapy adoption expands, the ability to ensure safety and accuracy at speed will become a decisive factor in hospital procurement decisions.